Compare Elastic NV (ESTC) vs Summit Therapeutics Inc (SMMT) Price & Performance

Elastic (ESTC) trades at $76.64, up 0.42% today, with a bullish technical outlook as it trades above key moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.61 exceeding the $0.561 estimate. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Revenue growth is robust, projected to rise from $1.48B in 2025 to $1.7B in 2026, while net income is expected to turn positive at $368M.

The stock offers growth potential driven by AI partnerships and market leadership, but faces risks from high valuation multiples like a P/E of 22.26 and EV/EBITDA of 206.43. Analyst consensus is bullish with a $74.21 price target and no sell ratings, though RSI levels indicate overbought conditions. Key risks include competitive pressures and reliance on tech sector demand.

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.